Circassia Pharmaceuticals PLC’s (CIR) “Buy” Rating Reaffirmed at Numis Securities Ltd
Circassia Pharmaceuticals PLC (LON:CIR)‘s stock had its “buy” rating reaffirmed by investment analysts at Numis Securities Ltd in a research note issued to investors on Thursday. They currently have a GBX 180 ($2.32) price objective on the biopharmaceutical company’s stock. Numis Securities Ltd’s price objective indicates a potential upside of 104.55% from the stock’s previous close.
Separately, J P Morgan Chase & Co reaffirmed a “neutral” rating and set a GBX 120 ($1.55) price objective on shares of Circassia Pharmaceuticals PLC in a research note on Tuesday, May 23rd.
Shares of Circassia Pharmaceuticals PLC (LON:CIR) traded up 1.15% during trading on Thursday, reaching GBX 88.00. 445,469 shares of the company’s stock were exchanged. Circassia Pharmaceuticals PLC has a 52 week low of GBX 76.75 and a 52 week high of GBX 114.00. The firm’s market capitalization is GBX 250.47 million. The company’s 50-day moving average price is GBX 87.64 and its 200 day moving average price is GBX 91.99.
TRADEMARK VIOLATION WARNING: This news story was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/10/circassia-pharmaceuticals-plcs-cir-buy-rating-reaffirmed-at-numis-securities-ltd.html.
Circassia Pharmaceuticals PLC Company Profile
Circassia Pharmaceuticals plc is a specialty biopharmaceutical company focused on allergy and respiratory diseases. The Company operates through three segments: Allergy, which relates to a range of immunotherapy development products for the treatment of allergy; NIOX, which relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO), and Respiratory, which relates to the portfolio of asthma and chronic obstructive pulmonary disease product candidates.
Receive News & Ratings for Circassia Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Circassia Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.